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Abstract
SPARC up-regulation is a poor prognostic factor in head and neck cancer. It was hypothesized that because of
a SPARC-albumin interaction, tumoral SPARC facilitates the accumulation of albumin in the tumor and increases
the effectiveness of albumin-bound paclitaxel (nab-paclitaxel). This hypothesis was tested by correlating the re-
sponse to nab-paclitaxel and SPARC tumor expression in a retrospective analysis of a 60-patient clinical study
of nab-paclitaxel as monotherapy against head and neck cancer. Sixteen tumor specimens were available for anal-
ysis. There were 11 responders (CR/PR) and 5 nonresponders (SD/PD) among the 16 nab-paclitaxel–treated pa-
tients (12/16 SPARC-positive, 75%). Response to nab-paclitaxel was higher for SPARC-positive patients (10/12,
83%) than SPARC-negative patients (1/4, 25%). The SPARC-negative patients exhibited significantly lower re-
sponse than the overall response rate among all 60 patients (1/4, 25% vs 45/60, 75%). Although preliminary, data
are supportive of the hypothesis that SPARC overexpression may correlate with response to nab-paclitaxel. If con-
firmed in larger studies, treatment with nab-paclitaxel may convert a poor prognosis SPARC-positive patient pop-
ulation into a group with better clinical outcomes.
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Introduction
Head and neck cancer, which includes cancers of the oral cavity, lar-
ynx, nasal passages, pharynx, and salivary glands, accounts for ap-
proximately 3% of adult malignancies in the United States [1]. In
2008, there were estimated 47,560 new cases of head and neck can-
cers in the United States, with 11,260 mortalities [1]. For advanced
disease, treatment regimens include surgery, radiotherapy, chemo-
therapy, and potentially targeted therapy. Intra-arterial infusion che-
motherapy for head and neck cancer is associated with favorable
pharmacokinetics, lower systemic toxicity, and high tumor response
rate [2]. However, this route of administration was not available for
paclitaxel until the advent of albumin-bound paclitaxel (nab-paclitaxel).
Albumin-bound paclitaxel (nab-paclitaxel), also known as Abraxane,
or ABI-007, is a Cremophor-free, albumin-bound 130-nm particle
form of paclitaxel (Abraxane package insert). It received approval
from the Food and Drug Administration in January 2005 for the
treatment of breast cancer after failure of combination chemotherapy
for metastatic disease or relapse within 6 months of adjuvant chemo-
therapy. Compared with conventional paclitaxel formulation known
as Taxol (Bristol-Myers Squibb Co, Princeton, NJ), nab-paclitaxel
does not require the use of Cremophor-EL, thus avoids the severe
toxicities associated with this vehicle.
Clinical studies by Damascelli et al. [3] have demonstrated that
the intra-arterial nab-paclitaxel chemotherapy by percutaneous cath-
eterization has great promise in the treatment of advanced squamous
cell carcinomas (SCCs) of the head and neck. In a phase 1 study with
31 advanced patients, the maximum tolerated dose (MTD) was de-
termined to be 270 mg/m2 every 4 weeks. The toxicity was accept-
able, with the dose-limiting toxicity being myelosuppression with
grade 4 neutropenia in one patient. The treatment showed strong
antitumor activity with an overall response rate (ORR) of 75.85%
(22 of 29 assessable patients, with 3 complete responses [CRs] and
19 partial responses [PRs]). In an ensuing phase 2 trial [4], 60 pre-
viously untreated patients with locally advanced SCC of the oral
cavity, oropharynx, or hypopharynx were treated with intra-arterial
nab-paclitaxel every 3 weeks at an initial dose of 230 mg/m2 and
subsequently a reduced dose of 150 mg/m2. The chemotherapy
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was highly effective and produced complete or partial responses in 45
of 60 patients (ORR: 75%; CR: 15 patients, 25%; PR: 30 patients,
50%). In a group of 23 previously untreated patients with advanced
SCC of the tongue [5], treatment with intra-arterial nab-paclitaxel at
150 to 230 mg/m2 every 3 weeks resulted in clinical and radiologic
objective responses in 18 patients (ORR: 78%; CR: 6 patients, 26%;
PR: 12 patients, 52%) and acceptable toxicity. Overall, intra-arterial
nab-paclitaxel demonstrated safety and strong efficacy against SCC of
head and neck and consistently exhibited high tumor response rates
of approximately 75% in clinical studies.
The effectiveness of nab-paclitaxel as a single agent against head
and neck cancer in these trials prompted the question whether tumor-
secreted SPARC, because of its albumin-binding properties, could en-
hance the accumulation of albumin in tumor tissue and hence influence
the response to nab-paclitaxel [6]. SPARC was first identified as a glyco-
sylated 43-kDa secreted protein with high binding affinity to albumin
[7]. SPARC modulates the cell and extracellular matrix interactions and
acts as a key regulator of critical cellular functions such as proliferation,
survival, and cell migration [8]. In normal tissues, SPARC expression is
limited to bone and tissues undergoing development, remodeling, and
repair [9]. However, SPARC expression is known to be upregulated in
many different tumors and plays important roles in tumor progres-
sion [10]. SPARC can be produced by both cancer cells and the reactive
stromal cells and is found to be highly expressed in the tumor-stroma
interface of the invading tumors and induced by hypoxia and acidity
[11]. Overexpression of SPARC is associated with increased tumor inva-
sion and metastasis, leading to poor prognosis in multiple tumor types,
including breast, prostate, esophagus, gastric, colorectal, liver, lung, kid-
ney, melanoma, bladder, head and neck, thyroid, and brain cancers [10].
Specifically for head and neck cancer, SPARC overexpression has been
demonstrated to be a prognostic factor for short disease-free survival and
poor overall survival (OS) [12,13].
Previously, we have shown that SPARC in the tumor can facilitate
the accumulation of albumin-bound drugs [6]. Various proliferating
tumors are known to accumulate albumin as a nutrition and nitrogen
source for de novo protein synthesis [14]. nab-Paclitaxel takes advan-
tage of this important aspect of tumor biology by using the gp60 and
caveolae-mediated albumin transport pathway to traverse the blood
vessel endothelial lining into the tumor wherein it is preferentially re-
tained by tumoral SPARC. The proposed mechanism of action for
nab-paclitaxel as shown in Figure 1 explains the observed almost dou-
bling of response to nab-paclitaxel compared with Taxol during a
phase 3 clinical trial in metastatic breast cancer [15]. The purpose
of this retrospective clinical study was to investigate the correlation
between SPARC tumoral expression and response to nab-paclitaxel as
a monotherapy against head and neck cancer to further explain the
observed high response rate of solid tumors to nab-paclitaxel.
Materials and Methods
Tumor and Normal Tissues
Human head and neck tumor tissue array and normal human tis-
sues were obtained from Cybrdi (Frederick, MD). Head and neck
tumor tissues (N = 119) were taken from various regions including
cheek (n = 18), jaws (n = 6), larynx (n = 33), tongue (n = 27), lip (n =
6), gingival (n = 3), nasopharynx (n = 3), ethmoid sinus (n = 3), and
nose (n = 20). Normal tissues (N = 25) were taken from regions ad-
jacent to tumors and consisted of gingival (n = 9), tongue (n = 6),
and tonsil (n = 10). Biopsies from 16 head and neck cancer patients
receiving intra-arterial nab-paclitaxel treatment were provided by
Figure 1.Mechanisms for the transport and accumulation of albumin-bound paclitaxel in tumors. The transport of albumin-bound pacli-
taxel complexes across the endothelial barrier of tumor microvasculature is facilitated by gp60 receptor and caveolin-1 mediated trans-
cytosis. The accumulation of albumin-bound paclitaxel in tumor is enhanced by the presence of albumin-binding protein SPARC in the
tumor interstitium. Entry of paclitaxel into the cells (tumor or stromal) likely occurs by rapid exchange of albumin-bound paclitaxel to the
lipidic components of the cell membrane. The mechanism for cellular uptake remains to be elucidated.
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Dr. Bruno Damascelli (Istituto Nazionale Tumori, Milano, Italy) [4].
Tumors (N = 16) consisted of tongue (n = 6), tonsil (n = 6), palate
(n = 2), gum (n = 1), and oropharynx (n = 1). As control, normal
adult human head and neck tissue array was obtained from Cybrdi
(N = 16), consisted of samples from tonsil (n = 10) and tongue (n = 6).
Immunohistochemical Staining
Expression of SPARC in head and neck cancer and normal tissues
was examined by immunohistochemical staining, performed as de-
scribed previously [16]. Briefly, paraffin-embedded sections were
washed thrice for 10 minutes each with Hemo De (Fisher Scientific,
Pittsburgh, PA), rinsed in absolute ethanol, and then treated with
methanol containing 0.5% hydrogen peroxide for 30 minutes. The
slides were then washed in water, incubated in PBS-Tween (0.1%
Tween 20 in PBS) for 10 minutes, followed by blocking in Dulbecco’s
modified Eagle’s medium containing 10% FBS for 1 hour. The slides
were then incubated with 10 μg/ml of polyclonal antihuman SPARC
antibody (R&D Systems, Minneapolis, MN) in PBS-Tween for
1 hour, washed twice in PBS-Tween for 5 minutes each, and in-
cubated for 1 hour with 1:100 dilution of antirabbit horseradish
peroxidase–conjugated antibody (Pierce, Rockford, IL). Sections
were washed in PBS-Tween and incubated for 10 minutes in the
substrate solution (100 μl of 2.4 mg/ml 3-amino-9-ethylcarbazole
in N ′N ′-dimethyl formamide, 1 ml of acetate buffer, pH 5.2, and
5 μl of 30% wt/wt hydrogen peroxide), counterstained with Mayer’s
hematoxylin, and mounted with Crystal Mount (BioMeda, Corp,
Foster City, CA). The staining was scored on a 0 to 4 scale (0 =
no staining, 4 = strong positive). Positive SPARC expression was de-
fined as ≥2+ staining and negative SPARC expression was defined as
<2+ staining. The immunohistochemical scoring was performed
blinded by a trained pathologist. The SPARC scoring in this study
was an overall score of the tumor, comprising both the tumor and
stromal cells, as both tumoral SPARC and stromal fibroblast SPARC
have been shown to be important factors determining prognosis.
Patient Group and nab-Paclitaxel Treatment
Tumor blocks from 16 patients analyzed retrospectively for
SPARC status were part of the phase 2 clinical study with 60 patients
by Damascelli et al. [4]. The 16 randomly chosen patients all had
biopsy-proven SCC of the oral cavity, oropharynx, or hypopharynx
(stage T3/T4, any nodal stage). As described previously, each patient
received a minimum of two to a maximum of four intra-arterial infu-
sions of nab-paclitaxel (dose range, 150-230 mg/m2), with an interval
of 3 weeks between each infusion. The intra-arterial administration
was performed by percutaneous catheterization of the femoral artery.
After intra-arterial nab-paclitaxel chemotherapy, patients received de-
finitive treatment, which included surgery, chemotherapy, radiother-
apy, or combination therapy.
Outcome Evaluation and Statistical Analysis
Response to treatment was evaluated by physical examination and
CT performed before each intra-arterial infusion and 3 weeks after
the last treatment cycle. Objective response was assessed with the
clinical and radiological method that provided the best evidence.
The response was classified as complete response (CR, complete dis-
appearance of all clinical and radiologic evidence of disease), partial
response (PR, ≥50% decrease in tumor size), stable disease (SD, <50%
decrease or <25% increase in tumor size), or tumor progression (PD,
>25% increase in tumor size). The correlation between tumor SPARC
expression status and clinical response to nab-paclitaxel was analyzed
by Fisher’s exact test using the Prism statistical program (GraphPad,
San Diego, CA).
Results
SPARC Is Overexpressed in Head and Neck Tumors
To confirm previous findings of SPARC overexpression in head
and neck cancer, we examined SPARC expression by immunohis-
tochemical staining of human head and neck tumor tissue array. In
the tissue array, 72 (61%) of 119 head and neck cancer tissues were
SPARC-positive (immunostaining score, ≥2+) compared with 0 (0%)
of 25 normal tissues (P < .0001, Fisher’s exact test). Among head and
neck cancers, SPARC expression was higher in tumor tissues from
tongue than those from other regions: tongue (22/27, 81% positive)
versus cheek (12/18, 68%), ethmoid sinus (2/3, 67%), larynx (17/33,
52%), jaw (3/6, 50%), lip (3/6, 50%), nose (9/20, 45%), gingiva
(0/3, 0%), and nasopharynx (0/3, 0%). Representative immunohis-
tochemical stainings are shown in Figure 2.
SPARC Is Overexpressed in Head and Neck Cancer Patients
Enrolled in the Current Trial
We further evaluated SPARC status in tumor samples from 16
head and neck cancer patients enrolled in the phase 2 intra-arterial
nab-paclitaxel clinical trial conducted by Damascelli et al. [4]. A large
percentage of the tumors (12 of 16 patients, 75%) were SPARC-
positive, compared with 0% of normal tissues (0 of 16 samples from
Cybrdi normal head and neck tissue array; P < .0001, Fisher’s exact
test). There was no correlation between SPARC status and tumor/
nodal stage. For tumors at specific sites, 83.3% of tongue tumors
(5/6) overexpressed SPARC, compared with 0% of normal tongue
(0/6; P = .015, Fisher’s exact test). SPARC was overexpressed in
83.3% of tonsil tumors (5/6), compared with 0% of normal tonsil
(0/10; P = .001, Fisher’s exact test). Representative immunohisto-
chemical stainings are shown in Figure 3.
SPARC Expression Correlates with Response to
Albumin-Bound Paclitaxel
The ORR to nab-paclitaxel among 60 patients in the study was
75% (45/60), with 25% CR (15 patients) and 50% PR (30 patients)
[4]. The 16 patients with available SPARC status included 11 re-
sponders (3 CR, 8 PR) and 5 nonresponders (2 SD, 3 PD). Detailed
results from the 16 patients are summarized in Table 1. Response to
nab-paclitaxel (CR and PR) was higher for SPARC-positive patients
(10 responders in 12 patients, 83%) compared with SPARC-negative
patients (1 responder in 4 patients, 25%), P = .06, Fisher’s exact test.
Furthermore, the SPARC-negative patients exhibited significantly
lower response rate compared with the ORR in the study (1/4 =
25% vs 45/60 = 75%, P < .05, Fisher’s exact test). No correlation
was observed between tumor response and tumor/nodal stage. Over-
all, there was correlation between positive SPARC expression and fa-
vorable response to nab-paclitaxel in this group of 16 head and neck
cancer patients (Table 2).
Correlation was also observed in a subgroup of tongue and tonsil
cancer patients among the 16 head and neck cancer patients. Among
the six patients with cancer of the tongue, five patients (83.3%) re-
sponded to nab-paclitaxel treatment (0 CR/5 PR). Five patients were
SPARC-positive and four of them were responders. Among the six
patients with cancer of the tonsil, five patients (83.3%) responded
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Figure 3. SPARC overexpression in head and neck cancer patients (tongue cancer subgroup). SPARC expression was analyzed by im-
munohistochemical staining in biopsy samples from patients with tongue cancers. Normal tongue tissue served as a control.
Figure 2. Overexpression of SPARC in human head and neck tumor tissue arrays. SPARC expression was analyzed by immunohisto-
chemical staining in human head and neck tumor and normal head and neck tissue arrays. SPARC was overexpressed in head and neck
cancer of different sites but not in normal tissues.
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to nab-paclitaxel treatment (3 CR/2 PR). There were five SPARC-
positive patients in this subgroup, and all of them were responders.
Discussion
SPARC has been proposed as an important factor affecting the
drug accumulation and tumor response of albumin-bound drugs
including nab-paclitaxel through the albumin-SPARC interaction
[15,17]. To better understand the reasons behind the improved re-
sponse rate for nab-paclitaxel, we analyzed SPARC expression levels
in head and neck cancer tissue array and patient biopsy samples and
correlated the SPARC status with clinical response. This study was
unique as it allowed us to examine response to nab-paclitaxel in a
monotherapy setting, without confounding factors from other anti-
cancer agents that are frequently used in combination with paclitaxel.
In a previous study by Borad et al. [18], SPARC was identified by
microarray across multiple tumor types as the gene most differentially
expressed in patients with advanced cancer, with overexpression over
normal tissues being observed in 68% of 112 tumors. Tumor types
with a particularly high level of SPARC positivity were melanoma
(88%), pancreatic cancer (81%), and breast (67%). Consistent with
this result, our study showed that there was overexpression of SPARC
in a large percentage of head and neck cancers but not in normal
tissues. In the tumor tissue array, 61% of head and neck cancer tis-
sues were SPARC-positive compared with 0% of normal tissues. Fur-
ther, in 16 head and neck cancer patients in our clinical study, 75%
were SPARC-positive, compared with 0% of samples from Cybrdi
normal tissue array. For the subgroup of six patients with tongue tu-
mors, 83.3% overexpressed SPARC, compared with 0% of normal
tongue tissues. Our data expanded on the nearly universal observa-
tion that SPARC is predominantly overexpressed in solid tumors in-
cluding head and neck cancer [10].
In previous studies, a positive SPARC status was a strong indepen-
dent prognostic indicator for short disease-free interval (DFI) and
poor OS in head and neck cancer patients [12], and SPARC positiv-
ity in Stage II tongue carcinoma was also a poor prognostic factor for
OS [13]. In a study by Chin et al. [12], SPARC mRNA levels were
identified by microarray to be upregulated in tumor tissues compared
with matching normal tissues. Immunohistochemistry confirmed
SPARC expression in tumor cells as well as stromal fibroblasts both
within the tumor and adjacent to it. In a group of 62 head and neck
cancer patients, SPARC-positive patients (n = 18) was associated with
shorter DFI (mean, 28.3 months) compared with SPARC-negative
patients (n = 44; mean, 59.4 months; P < .002). SPARC positivity
was also an indicator for poor OS (mean, 34.94 months for SPARC-
positive vs 59.84 months for SPARC-negative patients; P = .018).
The association of SPARC status with DFI and OS was even more
significant (P < .001) when analyzed in combination with PAI-1 and
uPA expression. In a separate study by Kato et al. [13] with 86 patients
of tongue carcinoma, 38 patients were diffusely or partly SPARC-
positive, whereas 48 patients were SPARC-negative. The 5-year OS
rate was 37.5% for the patients intensively positive for SPARC, com-
pared with 63.2% for partly SPARC-positive patients and significantly
lower than the survival rate of 70.7% for SPARC-negative cases (P <
.05, Wilcoxon test). In 23 stage II cases, the 5-year survival rate was
significantly lower in the intensively and partly SPARC-positive cases
(28.6%) than in the SPARC-negative cases (91.7%; P < .001,Wilcoxon
test), whereas the frequency of the postoperative metastasis was sig-
nificantly higher in SPARC-positive cases (5/8, 62.5%) than in the neg-
ative cases (1/15, 6.7%; P < .01, χ 2 test).
Although high levels of SPARC are generally associated with poor
prognosis in multiple tumor types, SPARC can also serve as a target
for albumin-based chemotherapies such as nab-paclitaxel because of
its albumin-binding activity. In vitro solid-phase binding assay has
revealed that SPARC binds to albumin in a saturable and specific
manner [6]. In both MX-1 breast tumor cells and tumor xenografts,
SPARC was shown to colocalize with albumin [19]. nab-Paclitaxel
achieved 33% higher intratumor paclitaxel concentration compared
with an equal dose of Cremophor-based paclitaxel in MX-1 tumor
xenografts [20]. Further, high-level SPARC expression is linked to
response to nab-paclitaxel in tumor xenograft models. In a study with
multiple tumor xenografts, the relative efficacy of nab-paclitaxel
compared with polysorbate-based docetaxel seemed to increase with
increasing SPARC expression in HER2-positive tumors [21]. nab-
Paclitaxel at sub-MTD was equal to or better than polysorbate-based
docetaxel at its MTD in PC3 prostate and HT29 colon tumors with
medium to high SPARC levels but not in MDA-MB-231/HER2+
breast tumors with low SPARC expression. In another study, SPARC-
overexpressing xenograft PC3/SP exhibited enhanced response to nab-
paclitaxel compared with wild type PC3 prostate tumor xenograft
(97% vs 84% tumor growth inhibition, and 36 vs 25 days in tumor
growth delay, P < .0001, analysis of variance) [6].
Consistent with preclinical results showing correlation between
SPARC and response to nab-paclitaxel, this study suggests that
SPARC could also be used to predict a favorable tumor response to
nab-paclitaxel treatment in a clinical setting in head and neck tu-
mors and in a subgroup of tongue and tonsil tumors. SPARC-positive
patients showed higher response to nab-paclitaxel compared with
SPARC-negative patients. The response rate among SPARC-negative
patients was also significantly lower than the ORR in the entire group
of 60 patients. The preclinical results above along with current data
showing overexpression of SPARC in head and neck cancers and
Table 1. Patient Data, SPARC Expression, and Response to nab-Paclitaxel in 16 Head and Neck
Cancer Patients.
Patient No. Site Staging Response SPARC
1 Left tonsil T3 N0 Complete Positive
2 Tongue T4 N2 A Partial Positive
3 Tongue T3 N2 A Partial Negative
4 Tongue T3 N0 Partial Positive
5 Gum T3 N0 Partial Positive
6 Tonsil T3 N0 Complete Positive
7 Tonsil T3 N0 Complete Positive
8 Tongue T3 N1 Partial Positive
9 Tongue T3 N0 Partial Positive
10 Tonsil T3 N0 Partial Positive
11 Tonsil T4 N2 B Partial Positive
12 Oropharynx T3 N0 Progression Positive
13 Tonsil T3 N0 Progression Negative
14 Palate T4 N0 Stable Negative
15 Tongue T3 N2 B Stable Positive
16 Palate T4 N0 Progression Negative
Table 2. Correlation of SPARC Expression with Response to nab-Paclitaxel in 16 Head and Neck
Cancer Patients.
SPARC Status Patients Responding Patients Nonresponding
Positive (n = 12) 10/12 (83%) 2/12 (17%)
Negative (n = 4) 1/4 (25%) 3/4 (75%)
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clinical response support a potential correlation of response to nab-
paclitaxel with SPARC positivity in head and neck cancer. Although
this initial study of the SPARC correlation to clinical response was
limited by the small number of patients, a similar correlation has also
been observed in other tumor types. In particular, SPARC is also as-
sociated with improved response to nab-paclitaxel and gemcitabine
with promising results in patients with advanced pancreatic cancer
in a disease-specific modified phase 1 trial [22]. The use of SPARC
as a predictive biomarker for nab-paclitaxel treatment requires further
verification, and several larger ongoing clinical studies in multiple tu-
mor types are investigating this correlation.
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